NASDAQ:HEPA Hepion Pharmaceuticals (HEPA) Stock Price, News & Analysis → $9 AI Model with 90% Win Rate? (From Trade Machine) (Ad) Free HEPA Stock Alerts $1.18 +0.08 (+7.27%) (As of 06/11/2024 ET) Add Compare Share Share Today's Range$1.08▼$1.2150-Day Range$1.08▼$2.6452-Week Range$1.05▼$12.88Volume15,403 shsAverage Volume28,991 shsMarket Capitalization$6.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Hepion Pharmaceuticals alerts: Email Address Ad Trade MachinePotentially Pocket $767/Day with AIWhat if I told you it could take just $9… To win 90% of your options trades?Click here to see this revolutionary AI model in action… About Hepion Pharmaceuticals Stock (NASDAQ:HEPA)Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Read More HEPA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HEPA Stock News HeadlinesMay 21, 2024 | investorplace.comHEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024April 28, 2024 | nytimes.comU.S. Lags Behind Other Countries in Hepatitis-C TreatmentApril 22, 2024 | finance.yahoo.comWhy Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?April 22, 2024 | investorplace.comWhy Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?April 22, 2024 | investorplace.comWhy Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?April 21, 2024 | stockhouse.comHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' TrialApril 20, 2024 | finanznachrichten.deHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' TrialApril 19, 2024 | marketwatch.comHepion Pharma to Wind-Down Phase 2b Ascend-NASH Trial, Cites Resource ConstraintsApril 19, 2024 | marketwatch.comHepion Pharma Shares Plunge 31% After Disclosing Plans to Wind Down TrialApril 19, 2024 | finance.yahoo.comHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ TrialApril 19, 2024 | globenewswire.comHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' TrialApril 17, 2024 | msn.comHEPA Stock Earnings: Hepion Pharmaceuticals Beats EPS for Q4 2023April 14, 2024 | morningstar.comHepion Pharmaceuticals Inc HEPAMarch 24, 2024 | investing.comHepion Pharmaceuticals Inc (HEPA)March 6, 2024 | globenewswire.comHepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael PurcellFebruary 16, 2024 | finance.yahoo.comHepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsFebruary 16, 2024 | globenewswire.comHepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsJanuary 3, 2024 | finance.yahoo.comHepion Pharmaceuticals to Present at NASH-TAG 2024December 7, 2023 | finanznachrichten.deHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesDecember 7, 2023 | realmoney.thestreet.comHepion Pharmaceuticals downgraded to Hold from Buy at BrooklineDecember 7, 2023 | marketwatch.comHepion Sets Restructuring; To Explore Strategic OptionsDecember 7, 2023 | finance.yahoo.comHepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesNovember 28, 2023 | finance.yahoo.comHepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development SummitNovember 28, 2023 | msn.comHepion Pharmaceuticals says Wijngaard buys 5K shares in coNovember 13, 2023 | finance.yahoo.comHepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver DiseaseSee More Headlines Receive HEPA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hepion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/16/2024Today6/12/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HEPA CUSIPN/A CIK1583771 Webwww.hepionpharma.com Phone(732) 902-4000Fax732-902-4100Employees22Year Founded2013Profitability EPS (Most Recent Fiscal Year)($9.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-304.79% Return on Assets-161.20% Debt Debt-to-Equity RatioN/A Current Ratio5.99 Quick Ratio5.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.29 per share Price / Book0.91Miscellaneous Outstanding Shares5,470,000Free Float5,366,000Market Cap$6.45 million OptionableNo Data Beta1.70 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. John T. Cavan (Age 66)Interim CEO & CFO Comp: $495.33kSharen PyatetskayaDirector of Investor RelationsDr. John Z. Sullivan-Bolyai (Age 76)Part-Time Consultant Dr. Stephen A. Harrison FACPM.D., Scientific Advisory Board Chair & Consultant Medical DirectorKey CompetitorsImunonNASDAQ:CLSNEquilliumNASDAQ:EQBiora TherapeuticsNASDAQ:BIORRenovoRxNASDAQ:RNXTAkari TherapeuticsNASDAQ:AKTXView All CompetitorsInsidersPeter WijngaardBought 2,500 shares on 11/27/2023Total: $7,625.00 ($3.05/share)Peter WijngaardBought 2,500 shares on 11/24/2023Total: $7,725.00 ($3.09/share)Peter WijngaardBought 1,000 shares on 9/19/2023Total: $5,640.00 ($5.64/share)Robert T FosterBought 1,600 shares on 9/18/2023Total: $8,960.00 ($5.60/share)Peter WijngaardBought 2,000 shares on 9/15/2023Total: $11,200.00 ($5.60/share)View All Insider Transactions HEPA Stock Analysis - Frequently Asked Questions Should I buy or sell Hepion Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hepion Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" HEPA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HEPA, but not buy additional shares or sell existing shares. View HEPA analyst ratings or view top-rated stocks. How have HEPA shares performed in 2024? Hepion Pharmaceuticals' stock was trading at $3.24 at the start of the year. Since then, HEPA stock has decreased by 63.6% and is now trading at $1.18. View the best growth stocks for 2024 here. Are investors shorting Hepion Pharmaceuticals? Hepion Pharmaceuticals saw a decline in short interest during the month of May. As of May 31st, there was short interest totaling 25,700 shares, a decline of 21.6% from the May 15th total of 32,800 shares. Based on an average daily trading volume, of 39,700 shares, the short-interest ratio is presently 0.6 days. Currently, 0.5% of the shares of the stock are sold short. View Hepion Pharmaceuticals' Short Interest. When is Hepion Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our HEPA earnings forecast. How were Hepion Pharmaceuticals' earnings last quarter? Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announced its quarterly earnings results on Tuesday, April, 16th. The company reported ($2.42) earnings per share (EPS) for the quarter. When did Hepion Pharmaceuticals' stock split? Hepion Pharmaceuticals shares reverse split on Thursday, May 11th 2023. The 1-20 reverse split was announced on Thursday, May 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Hepion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hepion Pharmaceuticals investors own include Bausch Health Companies (BHC), Axsome Therapeutics (AXSM), Archrock (AROC), Alector (ALEC), AIM ImmunoTech (AIM), Applied Genetic Technologies (AGTC), Abbott Laboratories (ABT) and Ambev (ABEV). How do I buy shares of Hepion Pharmaceuticals? Shares of HEPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HEPA) was last updated on 6/12/2024 by MarketBeat.com Staff From Our PartnersYour Special Report - Top 7 Summer StocksSummer is almost Here! I would like to give you a special report that could help boost your portfolio this sum...StockEarnings | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | Sponsored$9 AI Model with 90% Win Rate?What if I told you it could take just $9… To win 90% of your options trades?Trade Machine | SponsoredThe Hidden Tax Advantages of America’s #1 Inheritance StockWall Street Millionaire: BUY "America's #1 Legacy Stock" The man CNBC called "The Prophet" bought AAPL at $...Stansberry Research | SponsoredBill Clinton Backing Biden Replacement???Louis Navellier — a frequent guest at Mar-a-Lago — ruffled many in his own circles when he declared over a yea...The Freeport Society | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.